6/09/22

ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

E&P HEALTHCARE CONFERENCE PRESENTATION

EMVision Medical Devices Limited (ASX:EMV) ("EMVision" or the "Company"), a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to provide a copy of the presentation to be given by EMVision's CEO and Managing Director, Dr Ron Weinberger, at the E&P Healthcare Conference, September 2022.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys
Investor Relations
+61 400 400 380
Andrew.keys@keysthomas.com

Sling & Stone
Media and Communications
emvision@slingstone.com
02 8073 5390

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision's Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a $1.2 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

EMVISION

www.emvision.com.au

E&P HEALTHCARE CONFERENCE

Electromagnetic imaging to revolutionise stroke diagnosis and monitoring

SEPTEMBER 2022

ASX:EMV

DISCLAIMER

This presentation has been prepared by EMVision Medical Devices Limited ("EMVision" or "the Company"). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in EMVision in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors.

Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Similarly, past performance, including information concerning historical cash burn rates, should not be seen as indicative of future performance.

Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of EMVision. To the maximum extent permitted by law, EMVision and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

An investment in EMVision securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of EMVision. EMVision does not guarantee any rate of return or the absolute or relative investment performance of EMVision securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

OVERVIEW

EMVision is an innovative medical device company developing world first electromagnetic portable brain scanner products to address significant unmet needs

- Founded in 2017
- Experienced team (including key ex-Nanosonics leaders)
- "Zero to one" technology
- Best-in-breed partnerships and clinical collaborations
- Significant non-dilutive grant funding
- Multi-billion-dollar market opportunity

CAPITAL STRUCTURE

Headquarters:
4.01, 65 Epping Road, Macquarie Park
Sydney, Australia

ASX TICKER: EMV

Share Price (5 September 2022)	$1.50
Shares on issue	77.63m
Total Options on issue	3.55m
Performance Rights	6m
Market Capitalization	$116.4m
Enterprise Value	$109.6m
Cash Balance (30 June)	$6.8m
MRFF/ASA Non-dilutive Grant Funds*	$6.2m
MMI Non-dilutive Grant Funds	$5m

- **Secured >$17m in non-dilutive funding since inception**
- **$6.8m cash balance at 30 June 2022, modest cash burn**
- **Further $11.2m ongoing non-dilutive grant funding sources**
- **Multi-centre clinical trials capital efficient at anticipated <$4m**
- **Founders, Management and Directors closely aligned to shareholders, holding approximately 20% of shares on issue**

**Remaining ASA grant funds as at 5th September 2022. See ASX release titled 'ASA & EMVision sign $8m project agreement' for further information on ASA partnership and conditions of staged funding.*

EMVISION IS CREATING WORLD FIRST PORTABLE BRAIN SCANNERS

Neuroimaging as is accessible today.

EMV 1st Gen, Neuroimaging anywhere.

BRINGING IMAGING TO WHERE STROKE OCCURS WILL SAVE LIVES

THE PROBLEM

- 1 in 4 adults will have a stroke in their lifetime
- 2 out of 3 strokes result in permanent disability
- 34% of total global healthcare expenditure is spent on stroke
- The average healthcare cost of stroke per person in the United States is USD $140,048

TIME IS BRAIN

Every 10 minutes can SAVE up to 20 MILLION brain cells

CURRENT

TRADITIONAL IMAGING TOOLS

- Mainstay imaging techniques, CT and MRI, produce excellent images but are for the most part large, **stationary and complex machines** that require specialist operators, **limiting their point-of-care accessibility**.
- Whether a new acute stroke or a complication of an existing stroke, **urgent brain imaging is required** before the correct triage, treatment or intervention decision can be made.

SOLUTION

EMVISION POINT-OF-CARE

- EMVision's product portfolio of **portable, light weight, affordable and easy to use brain scanners** fills this unmet need for point-of-care brain imaging wherever the patient is.

✓ Faster diagnosis, faster treatment
✓ Better monitoring
✓ Less disability
✓ Improved quality of life
✓ Significant healthcare & insurer savings

GEN 1

GEN 2

Gen 1 and 2 devices under development and their potential clinical utility is subject to successful clinical testing and validation.

Rochmah, Thinni Nurul et al. "Economic Burden of Stroke Disease: A Systematic Review."

FILLING A GAP WHERE NO ALTERNATIVE IMAGING SOLUTIONS READILY ACCESSIBLE

UNMET NEED FOR PRE-HOSPITAL AND BEDSIDE IMAGING ACROSS THE ENTIRE PATIENT JOURNEY

A typical patient journey & timeline

15 mins to 2.5hrs

Pre-hospital

<2.5 hours

Hospital ED



<3 hours

CT Image Studies

<24 hours

Treatment / Intervention

<24 hours 3 weeks

Bedside Monitoring

<3 weeks 3 years +

Rehabilitation

2nd GEN

Potential clinical use cases

- **Reliability segment LVOs to assist decision making** on transport to clot retrieval center versus local stroke unit or hospital
- **Reliably distinguish between haemorrhagic stroke versus ischaemic stroke**. Future in-field tPA opportunity

1st GEN

Potential clinical use cases

- Monitor response to therapy or surgical intervention & complications
- Decision support when CT or MRI not accessible
- Detect secondary bleeding earlier – routine brain scan to assess haemorrhagic transformation of ischaemic stroke
- Monitoring for post stroke oedema to allow earlier clinical detection and intervention
- Monitoring response to reperfusion therapy including restoration of blood flow and complications

Gen 1 and 2 devices under development and their potential clinical utility is subject to successful clinical testing and validation.

1ST GEN

DETECT CLINICALLY SIGNIFICANT CHANGES, AT THE BEDSIDE, WHEN TIME MATTERS.

- A portable, cost-effective, non-ionizing and safe brain scanner
- Capable of rapidly producing quality images of biological tissue to provide game-changing insights for clinicians by the bedside
- Single operator, trained healthcare professional, no radiographer required
- Rapid insights, targeting <5 minutes from scan to images
- Pursuing FDA De Novo pathway
- **Next steps: multi-site trial and regulatory approvals process**

Gen 1 value proposition is subject to successful development, clinical testing and validation.

POSITIVE MARKET FEEDBACK – 1ST GEN PORTABLE BRAIN SCANNER

- 20 US based stroke specialists, with involvement in purchasing processes, surveyed by IDR Medical. The upper proposed Gen 1 purchase price ranges were considered reasonable by 50% of the sample, and only 1 respondent did not accept any of the prices presented.



(USD)

Research by; IDR Medical Intelligence Driven Results

www.emvision.com.au

ENCOURAGING HEALTH ECONOMIC ASSESSMENT

Estimated Gen 1 potential financial benefits to a public hospital in Australia[1]

Reduction in Transportation Costs	**$120,000**
More efficient CT/MRI Utilization	**$150,000**
Improvement in Endovascular Clot Retrieval Resource Utilization	**$90,000**
Reduction in Length of Stay	**$78,000**
Estimated Annual Total Financial Benefit of one device (excluding annual cost of imaging system)	**$438,000**

Research & Modelling conducted by;

IMPACT HEALTH
ACCELERATING HEALTH INNOVATION

[1]Mid-range budget impact estimates for an Australian Public Hospital in AUD.

The savings estimated is from an Australian public hospital budget impact perspective and does not include post discharge patient outcomes related savings. Investors are cautioned that this study summary dated August 2021 is based on a number of assumptions, which are subject to change and may cause actual results to differ materially from those forecast. Investors should not place undue reliance on these results. The study is not indicative of the proposed unit pricing of EMVision's devices.

2ND GEN

ULTRA LIGHT WEIGHT DEVICE FOR STANDARD ROAD AND AIR AMBULANCES

- Lightweight scalable imaging solution with telemedicine capabilities, tablet operated.
- Designed to assist with remote diagnosis
- Portable, in ambulances and carried into the home of a patient – helps with immediate diagnosis and treatment
- Leveraging knowhow from 1st Gen, 2nd Gen R&D and product development running in parallel
- FDA 510(k) Pathway (anticipated to leverage Gen 1 approvals)
- **Next steps: advanced prototype fabrication and testing**



Gen 2 value proposition is subject to successful development, clinical testing and validation.

MORE LIVES COULD BE SAVED WITH OUR SCALABLE AND LIGHTWEIGHT 2nd GEN BRAIN IMAGING SOLUTION

- Mobile Stroke Units (MSU) essentially bring the stroke unit to the patient, providing faster diagnosis and treatment, improving disability outcomes
- However, the model is resource intensive (including radiographer) and requires an expensive specialised vehicle ($1.5m+) and thus is not generalisable for scale-up
- EMV 2nd Gen offers a scalable solution that is portable, ultra lightweight and telemedicine enabled, deployable by trained paramedics in any road or air ambulance
- EMV is partnering with the Australian Stroke Alliance (ASA) to develop and validate the Gen 2 to transform pre-hospital stroke care

A Mobile Stroke Unit (MSU)

Inside a multi-million-dollar MSU today



Prospective, Multicenter, Controlled Trial of Mobile Stroke Units
Grotta JC et al. DOI: 10.1056/NEJMoa2103879

www.emvision.com.au

Gen 2 value proposition is subject to successful development, clinical testing and validation.

UNIQUE TECHNOLOGY PLATFORM

- Safe, portable, fast and accessible imaging modality
- IP portfolio spans software, hardware and multiple indications
- Successful proof-of-principle study completed with 50 confirmed stroke patients at Brisbane's Princess Alexandra hospital
- Algorithms refined in this study and observed to accurately classify stroke type (98%) and localise quadrant of stroke (78%)
- EMVision's technology has been published in:

frontiers in Neurology — source: https://doi.org/10.3389/fneur.2021.765412

Stroke — source: https://doi.org/10.1161/str.53.suppl_1.129

SHARED UNDERLYING PRINCIPLES

NON-DESTRUCTIVE TESTING
Microwave frequency
2 – 18 GHz

SECURITY
Millimeter frequency
10 - 80 GHz

ELECTROMAGNETIC IMAGING
Microwave frequency
500 MHz – 2 GHz

www.emvision.com.au

EMVISION

Low energy electromagnetic pulses are used to provide a mobile, and rapid neuroimaging modality for pre-hospital and bedside evaluation of patients based on the dielectric properties of the tissue.



Patient examples from pilot study.

SOC = Standard of Care imaging (CT or MRI)
EMV = EMVision technology.

In these patient examples pathologies highlighted blue were classified as ischemic stroke and those highlighted red were classified as hemorrhagic stroke.

Please refer to the Company's ASX announcement titled "EMVision Reports Very Encouraging Pilot Clinical Trial Data" released on 28th October 2020 and "Clinical Trial Data Drives Further Confidence for Expanded Studies" released 30th May 2021 for further details on the study. The algorithms may be subject to further refinement and investors should note there is no guarantee the algorithms will replicate the same level of accuracy on larger data sets without further refinement, or at all.

CLINICAL TRIAL ROADMAP – GEN 1

LOCATION

Site 1 - Liverpool Hospital
Site 2 - Royal Melbourne Hospital
Site 3 - Princess Alexandra Hospital

Sites will be activated in a staggered manner, commencing with Liverpool Hospital.

PARTICIPANTS

Presenting to emergency department with suspected stroke

REPORTING

The Company expects to provide updates to the market as it reaches relevant milestones and endpoints throughout the clinical testing

DURATION

Anticipated to be 12+ months

TRIAL DESIGN	*Pre-validation Phase*		*Validation Phase*
PATIENT COHORT	**Stage 1**: 30 Healthy participants **Stage 2**: Up to 150 Acute stroke/stroke mimic participants **Stage 3**: To be advised as required	**Regulatory body engagement**	Endpoints and sample size will be confirmed during the pre-validation phase
ENDPOINTS	• Hardware verification • Stroke mimic and acute stroke Data to enhance AI algorithms • Safety		• Efficacy (sensitivity/specificity) • Safety

SCANNING PROCESS FOR A TYPICAL STROKE PATIENT

Admission	**+24 Hours**	**3-5 Days later**
Emergency Department	Radiology / In-ward	Radiology / In-ward
CT + EMV Scans	CT and/or MRI + EMV Scans	CT and/or MRI + EMV Scans

The indicative trial roadmap and timetable is a guide of EMVision's intentions at the date of this presentation only. EMVision reserves the right to vary this plan and timetable at its discretion, and further notes the above timings are subject to change due to circumstances outside of its control.

ATTRACTIVE REVENUE MODELS

- **Traditional Capex or innovative Opex pricing model offerings to provide buyer flexibility. Direct or distributor sales channels.**
- **Significant consumable opportunity (including replaceable coupling media alongside a disposable cap, single use per patient scan)**

Consumables

Coupling media

Disposable cap

MONTHLY SUBSCRIPTION MODEL (GEN 1)

- Target ~$8,000 USD / month (subject to term)
- Delivery of the unit and training
- Consumables (subject to quota)
- Software upgrades
- Potential integration into PACS and EMR
- Access to cloud storage and viewing
- Routine maintenance included

CAPITAL EQUIPMENT & CONSUMABLES MODEL (GEN 1)

- Capital Equipment – Target: ~$150,000 USD
- Consumables (disposable cap, coupling media)
- Maintenance & Service
- Software upgrades

ADDRESSABLE MARKET

TOTAL INSTALLED BASE OPPORTUNITY

1st GEN ADDRESSABLE MARKET

US.	GER, FR, UK	AU	ROW
10,200	5,960	545	86,000
FIRST TARGETS			
1,600 PSC / CSC	**642 PSC / CSC**	**93 PSC / CSC**	

PSC = Primary Stroke Centre CSC = Comprehensive Stroke Centre

2nd GEN ADDRESSABLE MARKET

US.	EUROPE	AU	ROW
60,000	58,000	5,200	54,000



- 1st Gen deployment opportunities across stroke/neurology wards, ICUs, ED, cardiology, general wards
- First targets – tertiary stroke centers (PSC/CSC)
- 2nd Gen road/air ambulance market represents a further multi-billon dollar opportunity

EMV cautions investors that there are regulatory barriers and unique access challenges to each market and can be subject to varying rates of penetration. Estimates based on publicly available data. There are further regulatory hurdles to sell into ROW: China, India, Brazil, Mexico, South Korea, Spain, Italy and Canada.

SIGNIFICANT EXPERIENCE DEVELOPING AND COMMERICALISING MEDICAL DEVICES

Team of 30 across Sydney and Brisbane, in R&D and product development

Dr. Ron Weinberger
CEO and Managing Director

Former Executive Director and CEO of Nanosonics (ASX:NAN). Over 20-years' experience developing and commercializing medical devices.

Scott Kirkland
Co-founder and Executive Director

Oversees corporate affairs, commercial strategy and business development efforts & manages the company's participation in grant programs

Professor Stuart Crozier
Chief Scientific Officer

Co-inventor of underlying technology. Advancements in MRI technology now central to 65% of all MRI machines.

Robert Tiller
Head of Design

Over 25 years in medical device product design and commercialization, previously CEO of Tiller Design, in collaboration with Nanosonics R&D team developed the Trophon EPR device

Forough Khandan
Head of Product Development

Previously Program Manager at Nanosonics (ASX:NAN)

Emma Waldon
Company Secretary

Corporate advisory, capital markets and corporate governance experience in Australia and the UK.

Dr. Konstanty Bialkowski
Head of Technology Development, Co-inventor of underlying technology

Research interests in near-field and passive radar systems, multiple element antenna systems, and wireless communications.

Dr. Merrîcc Edgar-Hughes
Head of Quality & Regulatory Affairs

Formerly Regulatory Affairs Manager (Global) at Nanosonics. Experience with multiple successful FDA, CE, TGA registrations

PARTNERS & COLLABORATORS

TRACK RECORD OF SECURING AND ONGOING ACCESS TO NON-DILUTIVE FUNDING PROVIDES GOOD FLEXIBILITY

Metro South Health – Queensland Government

Clinical Research Partnership
Access to neurology, radiology and critical care expertise, access to simulation rooms and hospital infrastructure, advancement of bedside processes as well as input into technology development.

KEYSIGHT TECHNOLOGIES

Product Collaboration
Strategic OEM Agreement with Keysight Technologies (NYSE:KEYS) with exclusivity in the field of neuroimaging for the supply of the "fast sweep" feature in the VNA (core to the sensors inside EMV's portable brain scanner).

Australian Stroke Alliance

Clinical Development & Validation, Non-dilutive funding
ASA providing clinical expertise and $8M in non-dilutive funding to support clinical validation and deployment to transform pre-hospital stroke care

NVIDIA INCEPTION PROGRAM

Inception Member
NVIDIA Inception nurtures dedicated and exceptional startups who are revolutionizing industries with advances in AI and data science.

Australian Government – Department of Industry, Science, Energy and Resources – Modern Manufacturing Initiative

Manufacturing Grant
$5m non-dilutive federal manufacturing grant to establish first commercial production run

Australian Government – Department of Industry, Innovation and Science

The University Of Queensland AUSTRALIA

GE Healthcare

Princess Alexandra Hospital BRISBANE • AUSTRALIA

Commonwealth CRC-P Grant Program Collaborators

CRC-P grant supported an industry-led collaboration, including cash contribution from GE Healthcare, to develop and successfully test EMVision's earlier proof of principle prototype device

STRONG SUPPORT FROM THE CLINICAL COMMUNITY

"It cannot be underestimated how important this cutting-edge technology could become for future stroke management."

Professor Geoffrey Donnan AO
Stroke neurologist
Co-chair Australian Stroke Alliance, Past-president of World Stroke Organization

"The concept of bringing imaging to the patient will dramatically reduce times to administer life saving interventions such as thrombolysis and thrombectomy."

Professor Stephen Davis AO
Stroke neurologist
Co-chair Australian Stroke Alliance, Past-president of World Stroke Organization

"Equitable healthcare for remote Australians needs to overcome the tyranny of distance. Portable brain imaging is a crucial next step in bringing critical care to patients sooner."

Dr Mardi Steere
Executive General Manager Medical and Retrieval Services, Royal Flying Doctor Service Central Operations

"We have seen the EMVision technology advancing us towards the realisation of a novel imaging technology that will assist medical practitioners in making critical decisions, and critical interventions earlier, when time matters."

Dr David Cook
Intensivist

"A new phase will see mobile and portable technology move to the patient. We need advanced solutions beside the patient at the time of stroke, so that treatments can be delivered without delay."

Professor Michael O'Sullivan
Stroke neurologist

"With so many Australians and in particular a large proportion of Aboriginal and Torres Strait Islander patients living vast distances from stroke imaging, EMVision holds promise in being able to reduce stroke care inequity."

Dr. Angela Dos Santos
Stroke neurologist
Mobile Stroke Unit Expert

SUMMARY AND OUTLOOK

- Team of medtech experts that have successfully done this before
- Strong support from the leading minds in stroke care
- Increasing demand globally for point-of-care imaging
- Multi-billion-dollar market opportunity in stroke care
- Technology has additional applications for unmet needs in traumatic injury and adjacencies
- Multiple non-dilutive funding sources provide flexibility to support commercialization

Key Catalysts

- Clinical trial data
- Commercial partnerships
- Regulatory submissions and outcomes
- 2nd Gen prototype fabrication and testing

THANK YOU

EM VISION
ASX:EMV

WEBSITE
www.emvision.com.au

EMAIL
info@emvision.com.au

HEADQUARTERS
4.01, 65 Epping Road,
Macquarie Park
Sydney, Australia

APPENDIX

EXPERIENCED BOARD

John Keep
Non-Executive Chairman

As former CEO of Queensland Diagnostic Imaging, John grew the business to become the state's leading private imaging group and led the successful trade sale of the group

Dr. Ron Weinberger
CEO and Managing Director

Former Executive Director and CEO of Nanosonics' (ASX:NAN). Over 20-years' experience developing and commercializing medical devices.

Scott Kirkland
Executive Director

Co-founder of EMVision Medical Devices Ltd (ASX:EMV) Oversees EMVision's corporate affairs, commercial strategy and business development efforts.

Tony Keane
Non-Executive Director

A Director of National Storage Holdings Ltd (ASX:NSR) Previously held numerous roles with a major trading bank principally in business, corporate and institutional banking.

Geoff Pocock
Non-Executive Director

Over 20 years' experience in commercialisation, corporate finance and strategy
Currently Non-Executive Chairman of Argenica Therapeutics Ltd (ASX:AGN), and founder and former Managing Director of Hazer Group Limited (ASX:HZR)

Dr Philip Dubois
Non-Executive Director

Non-executive Director of Sonic Healthcare (ASX:SHL), and former CEO of their imaging division, and Executive Director from 2001 to 2020. Founder and former CEO and Chairman of Queensland X-Ray. Currently an Associate Professor of Radiology at the University of Queensland Medical School. Has served on numerous government and radiology group bodies

OUR HISTORY


Novel electromagnetic imaging techniques developed at UQ via modelling, simulations, lab testing – 400+ peer review papers
EMVision incorporated to acquire & commercialize IP
EMVision wins commonwealth CRC-P Grant with collaborators GE Healthcare, UQ and Metro South Health
Successful Healthy Human Trials
Invited to join Stroke Alliance
Demonstrates stroke subtype classification and localization capabilities
$8m Australian Stroke Alliance/MRF F Grant
Breakthrough technology developments – Dielectric Maps and Pulsatility
50 patient Clinical Testing Drives Further Confidence
Stroke
$5m MMI Grant Win to establish commercial manufacturing
Multicentre clinical trial
2007 - 2016
2017
2018
2019
2020
2021
2022
Proof of Concept Pre-Clinical Prototype featured in Nature
EMV develops pre-clinical prototype
EMV lists on the ASX
EMV develops Clinical Prototype
Encouraging preliminary images from pilot clinical trial
EMVision moves to NSW premises and builds out in-house commercial product team
EMV opens office at TRI Brisbane
Forms Metro South Health Clinical Research Partnership
EMVision's 1st Gen Device Unveiled
frontiers in Neurology
Strategic OEM Agreement signed with Keysight (NYSE:KEYS)